Several proteases, such as cysteine cathepsins, play central roles in the development of cancer and other diseases, but are considered difficult to drug because of their important physiological roles and the wide structural similarity between members of the same protease family. Our new peptide-based drugs overcome these issues because they are very specific for their protease target and can be delivered to specific cells, thereby avoiding any toxicity on healthy tissues. Our candidate drugs hold great promise for patients that do not respond to currently available therapies.
Founding team: Aaron Petruzzella PhD (CEO and Member of the Board), Giorgio Calderari PhD (Chairman of the Board), Alberto Petruzzella (Vice-Chair of the Board), Prof. Elisa Oricchio (EPFL), Prof. Bruno Correia (EPFL)
News
Milestones/News
